UNIVERSITY PARK, Pa. — A newly described protein could be an effective target for combating drug-resistant malaria parasites. The protein, the transcription factor PfAP2-I, regulates a number of genes involved with the parasite’s invasion of red blood cells, a critical part of the parasite’s complex life cycle that could be targeted by new anti-malarial drugs. A paper describing PfAP2-I and its role in the invasion process appears June 14, 2017, in the journal Cell Host & Microbe.
“The reality is that there are resistant parasites to every known anti-malarial drug,” said Manuel Llinás, professor of biochemistry and molecular biology at Penn State and lead author of the paper. “We need new drugs targeting different aspects of parasite biology.”
Nearly half of the world’s population lives in areas at risk of transmitting malaria, a serious and sometimes fatal disease that produces symptoms such as fevers, chills and flu-like illness. According to the World Health Organization, more than 212 million cases of malaria were reported in 2015, with an estimated 429,000 deaths, the majority of which occur in young children in sub-Saharan Africa.
Malaria is caused by Plasmodium parasites, which have a complex three-stage life cycle. After a parasite-carrying mosquito bites a person, the parasite infects liver cells, where it grows and multiplies. The parasites then invade red blood cells, where they multiply further, releasing daughter parasites, or merozoites, that in turn must invade new red blood cells. Symptoms of malaria are expressed during this cyclical 48-hour red blood cell life-stage.
“Quite simply, if you prevent the parasite from invading red blood cells, you prevent any disease,” said Llinás. “We want to understand how this invasion process is regulated at the genetic level. One of the unique features about Plasmodium is that it has very few transcription factors — proteins that bind to specific DNA sequences to direct which genes should be turned on and when. Most multi-celled organisms have hundreds of these regulators, but it turns out, so far as we can recognize, the parasite has a single family of transcription factors called Apicomplexan AP2 proteins. One of these transcription factors is PfAP2-I.”
PfAP2-I is the first known regulator of invasion genes in Plasmodium falciparum — the species that causes the deadliest form of malaria. In total, PfAP2-I specifically regulates more than 150 genes, 18 percent of which are known to be involved in the red blood cell invasion process. The new study also indicates that PfAP2-I likely recruits another protein, Bromodomain Protein 1 (PfBDP1), which was previously shown to be involved in the invasion of red blood cells. The two proteins may work together to regulate gene transcription during this critical stage of infection.
“Red blood cell invasion has been seriously considered for a long time as a candidate for anti-malarial vaccines,” said Llinás. “Many proteins that are found on the surface of the merozoite — proteins that help the parasite bind to and pull itself inside of a new red blood cell — have been targeted with vaccines, but they’ve all failed. Why? The surface proteins are very redundant, so unless you interfere with all of them, you can’t block invasion. But disrupting PfAP2-I would prevent the invasion program from ever getting turned on in the first place.”
Instead of targeting the merozoite surface proteins with a vaccine, a new drug could focus solely on inhibiting PfAP2-I. Preventing PfAP2-I from binding to DNA and initiating the expression of invasion genes, or preventing PfAP2-I from recruiting other important proteins like PfBDP1 would stop an infection before it even reaches the red blood cell stage. Because PfAP2-I does not have parallels in humans, a drug targeting this transcription factor may have the added benefit of specificity, making it safer with fewer potential side-effects in humans.
“Now that we know how the invasion process is regulated,” Llinás said, “we have a completely new angle for targeting the parasite through pharmacological intervention.”
In addition to Llinás, the research team includes Joana Santos, Gabrielle Josling, Philipp Ross, and Lindsey Orchard, postdoctoral researchers and research assistants at Penn State at the time of the research, and Preeti Joshi, Tracey Campbell, Ariel Schieler, and Ileana Cristea at Princeton University.
The research was funded by the U.S. National Institutes of Health, the Arnold and Mabel Beckman Foundation, and the Princeton Center for Quantitative Biology, and was supported by the Swiss National Science Foundation, EMBO, the Natural Sciences and Engineering Research Council of Canada, the New Jersey Commission on Cancer Research, the American Heart Association, and the Huck Institutes of the Life Sciences.
The Pennsylvania State University